GlassScriptPhysician profile
William Harrison Cheeley
NPI 1609396910
$3,488.63
in general payments reported to CMS, 2019-2025
35 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $276 · 2021: $743 · 2022: $654 · 2023: $646 · 2024: $793 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.75 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.26 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.86 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $300.51 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $259.60 | 2020-2024 | Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $170.27 | 2020-2025 | Nexletol |
| Abbvie INC. | $163.51 | 2020-2025 | Ubrelvy |
| Pfizer INC. | $125.69 | 2023-2025 | |
| Medtronic, INC. | $118.80 | 2022-2024 | Minimed 780g |
| Abbott Laboratories | $108.89 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $105.83 | 2022 | |
| Amarin Pharma, INC. | $95.80 | 2020-2021 | |
| Amgen INC. | $90.48 | 2022-2024 | Repatha |
| Currax Pharmaceuticals LLC | $85.27 | 2021-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $79.73 | 2021-2024 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.21 | 2023-2024 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $67.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $64.30 | 2020-2021 | |
| Exact Sciences Corporation | $63.13 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $60.97 | 2022-2024 | Quviviq |
| Innocoll Pharmaceuticals Limited | $54.75 | 2021-2022 | |
| Boston Scientific Corporation | $49.34 | 2024 | Wavewriter Alpha Prime 16 |
| Eisai INC. | $46.03 | 2021 | |
| Dexcom, INC. | $45.65 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.96 | 2025 | Shingrix |
| Regeneron Healthcare Solutions, INC. | $31.13 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $29.86 | 2024 | Oxlumo |
| Kiniksa Pharmaceuticals International, Plc | $25.98 | 2024 | Arcalyst |
| Sumitomo Pharma America, INC. | $22.84 | 2025 | Gemtesa |
| Astellas Pharma US INC | $21.81 | 2024 | Veozah |
| Dynavax Technologies Corporation | $20.60 | 2024 | Heplisav-B |
| Biocryst US Sales Co., LLC | $18.71 | 2021 | |
| Ermi LLC | $18.68 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.59 | 2024 | Voquezna |
| Pacira Therapeutics, INC. | $17.15 | 2021 | |
| Seqirus USA INC | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cheeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.